# Evaluate the Safety and Clinical Activity of HH2853

Source: https://onco.cc/trials/nct04390737/  
OnCo record `nct04390737` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HH2853 Tablets in non-Hodgkin lymphoma, epithelioid sarcoma and peripheral T-cell lymphomas, run by Haihe Biopharma Co., Ltd., now recruiting.

## Summary

Evaluate the Safety and Clinical Activity of HH2853 is a phase 1/2 interventional study registered as NCT04390737 by Haihe Biopharma Co., Ltd., with 254 participants planned, started 2020-09-08 and due to reach its primary completion in 2027-12-31. Interventions recorded: HH2853 Tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04390737
- Phase: 1/2
- Setting: A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of HH2853 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphomas or Advanced Solid Tumors
- Sponsor: Haihe Biopharma Co., Ltd.
- Enrolled: 254

## Sources

- ClinicalTrials.gov NCT04390737: https://clinicaltrials.gov/study/NCT04390737

## Connected records

- cancers: [Epithelioid sarcoma](https://onco.cc/cancers/epithelioid-sarcoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- companies: [Haihe Biopharma](https://onco.cc/companies/haihe-biopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct04390737.json